The Food and Drug Administration (FDA)
is revising the status reports section of the postmarketing annual
reporting requirements for human drug & biological products,
and requiring applicants to submit annual status reports for
certain postmarketing studies of licensed biological products. The
final rule describes the types of postmarketing studies covered by
these status reports, the information to be included in the
reports, and tye type of information that FDA would consider
appropriate for public disclosure. The agency is taking this action
to implement section 130 of the Food and Drug............
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.